Recently, MBS314, an innovative tri-specific antibody product developed by Beijing Mabworks Biotech Company Limited (hereinafter referred to as "Mabworks") in collaboration with Kangyuan Botron Biotechnology (Beijing) Limited, has obtained the Notice of Approval for Clinical Trial of Drugs issued by the State Drug Administration of the People's Republic of China (SDA), which authorizes the conduct of Phase I/II clinical trial for the treatment of multiple myeloma. Myeloma.

MBS314 is a new mechanism of tri-specific antibody targeting CD3/BCMA/GPRC5D for the treatment of multiple myeloma.MBS314 has a differentiated CD3 binding epitope, which is able to achieve low-affinity but long-lasting activation and killing effect with T-cells, with better safety; at the same time, it binds BCMA and GPRC5D with high affinity, which is able to overcome BCMA and GPRC5D tumor cell killing effect in the body of the patient. At the same time, the high affinity combination of BCMA and GPRC5D can overcome the heterogeneity of BCMA and GPRC5D expression in tumor cells in the patient's body, and can effectively kill and remove tumor foci, with better broad-spectrum and effectiveness.

Multiple myeloma is a malignant disease originating from the abnormal proliferation of clonal plasma cells in the bone marrow, and most patients experience one or more relapses throughout the course of the disease. As the disease recurs with each successive relapse, the degree and duration of remission for the patient usually decreases. At present, multiple myeloma remains a lethal and incurable disease.

Previously, MBS314 presented preclinical data at the American Association for Cancer Research Annual Meeting 2023 (AACR2023), in which ex vivo killing of primary tumor cells in patients and in vivo tumor growth experiments in mice showed that MBS314 has better tumor killing efficacy than CD3/BCMA and the CD3/GPRC5D dual antibody, and is expected to become a best-in-class multiple myeloma treatment MBS314 is expected to be the best in class in the treatment of multiple myeloma.

With the approval of this Phase I/II clinical trial, MBS314 will soon begin its exploration in the treatment of multiple myeloma, and is expected to bring more, more effective and safer drug choices to Chinese patients.

https://mp.weixin.qq.com/s/hD2cUFOLZE8RQBhGwBDqYQ